Literature DB >> 11005938

Drug-induced thrombocytopenia in the coronary care unit.

N M Patnode1, P J Gandhi.   

Abstract

Drug-induced thrombocytopenia is a phenomenon that causes significant morbidity and mortality among patients. Practitioners should be able to recognize the clinical manifestations of drug-induced thrombocytopenia, differentiate it from other causes, and manage it appropriately. Numerous case reports have documented drug-induced causes of thrombocytopenia. The following article focuses on the characteristics and management of drug-induced thrombocytopenia secondary to medications commonly encountered in the coronary care unit. Pharmacotherapeutic agents that are most commonly implicated in this setting include ticlopidine, unfractioned heparin, glycoprotein (GP)IIb/IIIa inhibitors, H(2)-receptor antagonists, quinidine and antibiotics. Case reports were obtained through a comprehensive search of the Medicine database and subsequently complemented by bibliographic reviews of the agents just specified. Reports that exhibited possible, probable, and definite associations with drug-induced thrombocytopenia are included in the article.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005938     DOI: 10.1023/a:1018766610796

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  123 in total

Review 1.  Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors.

Authors:  M Madan; S D Berkowitz
Journal:  Am Heart J       Date:  1999-10       Impact factor: 4.749

2.  Thrombocytopenia and hepatitis complicating ticlopidine therapy.

Authors:  N D Friedman; R Sitlington; R S Lodge
Journal:  Aust N Z J Med       Date:  1997-10

Review 3.  Heparin-induced thrombocytopenia: towards consensus.

Authors:  T E Warkentin; B H Chong; A Greinacher
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

4.  Thrombocytopenia induced by angiotensin converting enzyme inhibitors.

Authors:  B Grosbois; D Milton; C Beneton; D Jacomy
Journal:  BMJ       Date:  1989-01-21

5.  Immune-mediated thrombocytopenia associated with ranitidine therapy.

Authors:  P R Gibson; M E Pidcock
Journal:  Med J Aust       Date:  1986 Dec 1-15       Impact factor: 7.738

6.  Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody.

Authors:  E V Eisner; E B Crowell
Journal:  JAMA       Date:  1971-01-18       Impact factor: 56.272

7.  Acute thrombocytopenic purpura associated with "Septrin".

Authors:  K A Rickard; E Uhr
Journal:  Med J Aust       Date:  1971-04-03       Impact factor: 7.738

8.  Immune hemolytic anemia and thrombocytopenia secondary to quinidine: in vitro studies of the quinidine-dependent red cell and platelet antibodies.

Authors:  Z Zeigler; R K Shadduck; A Winkelstein; T K Stroupe
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

Review 9.  Thrombotic thrombocytopenic purpura associated with ticlopidine therapy.

Authors:  S F Leavey; J Weinberg
Journal:  J Am Soc Nephrol       Date:  1997-04       Impact factor: 10.121

10.  Cimetidine and ranitidine may not cross-react to cause thrombocytopenia.

Authors:  O Shalev; D Seror
Journal:  J Intern Med       Date:  1991-07       Impact factor: 8.989

View more
  4 in total

1.  Drug-induced thrombocytopenia: a population study.

Authors:  Maarten J ten Berg; Albert Huisman; Patrick C Souverein; Alfred F A M Schobben; Antoine C G Egberts; Wouter W van Solinge; Patricia M L A van den Bemt
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Vancomycin-Induced Thrombocytopenia: A Narrative Review.

Authors:  Mehdi Mohammadi; Zahra Jahangard-Rafsanjani; Amir Sarayani; Molouk Hadjibabaei; Maryam Taghizadeh-Ghehi
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

Review 3.  Drug-induced immune thrombocytopenia.

Authors:  Patricia M L A van den Bemt; Ronald H B Meyboom; Antoine C G Egberts
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Comparative evaluation of thrombocytopenia in adult patients receiving linezolid or glycopeptides in a respiratory intensive care unit.

Authors:  Zhaorui Zhang; Zhixin Liang; Huaidong Li; Liang'an Chen; Danyang She
Journal:  Exp Ther Med       Date:  2013-12-04       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.